




Instance: composition-en-c082813e7ff4dad923d73dee6e29eba2
InstanceOf: CompositionUvEpi
Title: "Composition for menveo Package Leaflet"
Description:  "Composition for menveo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc082813e7ff4dad923d73dee6e29eba2)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - menveo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Menveo is and what it is used for </li>
<li>What you need to know before you or your child are given Menveo </li>
<li>How to use Menveo </li>
<li>Possible side effects </li>
<li>How to store Menveo </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What menveo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What menveo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Menveo is a vaccine that is used for active immunization of children (from 2 years of age), 
adolescents and adults at risk of exposure to a bacterium named Neisseria meningitidis serogroups A, 
C, W-135 and Y, to prevent invasive disease. The vaccine works by causing your body to make its 
own protection (antibodies) against these bacteria. </p>
<p>Neisseria meningitidis serogroup A, C, W-135 and Y bacteria can cause serious and sometimes 
life-threatening infections such as meningitis and sepsis (blood poisoning). </p>
<p>Menveo cannot cause bacterial meningitis. This vaccine contains a protein (called CRM197) from 
the bacteria that cause diphtheria. Menveo does not protect against diphtheria. This means that 
you (or your child) should receive other vaccines to protect against diphtheria when these are due 
or when advised by your doctor. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take menveo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take menveo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Menveo if you or your child has:</p>
<ul>
<li>ever had an allergic reaction to the active substances or any of the other ingredients of this 
vaccine (listed in section 6) </li>
<li>ever had an allergic reaction to diphtheria toxoid (a substance used in a number of other 
vaccines) </li>
<li>an illness with high fever. However, a mild fever or upper respiratory infection (for example 
cold) itself is not a reason to delay vaccination. </li>
</ul>
<p>Warnings and precautions: </p>
<p>Talk to your doctor or nurse before you or your child are given Menveo if you or your child:</p>
<ul>
<li>have a weakened immune system. Little is known about the effectiveness of Menveo when 
administered to individuals with weakened immunity due to the use of immunosuppressive 
medications, or HIV infection, and other possible causes. It is possible that the effectiveness 
of Menveo could be reduced in such individuals. </li>
<li>have haemophilia or any other problem that may stop your blood from clotting properly, such as 
persons receiving blood thinners (anticoagulants). </li>
<li>receive treatment that blocks the part of the immune system known as complement activation, 
such as eculizumab. Even if you have been vaccinated with Menveo you remain at increased risk of 
disease caused by the Neisseria meningitidis groups A, C, W-135 and Y bacteria. </li>
</ul>
<p>Fainting, feeling faint or other stress-related reactions can occur as a response to any needle injection. 
Tell your doctor or nurse if you have experienced this kind of reaction previously. </p>
<p>This vaccine can only protect against meningococcal group A, C, W-135, and Y bacteria. It cannot 
protect against other types of meningococcal bacteria other than groups A, C, W-135 and Y, or against 
other causes of meningitis and sepsis (blood poisoning). </p>
<p>As with any vaccine, Menveo may not fully protect 100% of those who get the vaccine. </p>
<p>If you or your child received a dose of Menveo more than one year ago and remains at particular 
risk of exposure to meningococcal group A bacteria, consideration may be given to administering 
a booster dose to maintain protection. Your doctor will advise you if and when you should receive 
a booster dose. </p>
<p>Other medicines and Menveo </p>
<p>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. </p>
<p>Menveo may be given at the same time as other vaccinations but any other injected vaccines should 
preferably be given into a different arm from the site of the Menveo injection. </p>
<p>These include the following vaccines: tetanus, reduced diphtheria and acellular pertussis (Tdap), 
human papillomavirus (HPV), yellow fever, typhoid fever (Vi polysaccharide), Japanese encephalitis, 
rabies, hepatitis A and B and meningococcal group B (Bexsero). </p>
<p>Menveo s effect could be diminished when administered to individuals who are taking medicines that 
suppress the immune system. </p>
<p>Separate injection sites must be used if more than one vaccine is being administered at the same time. </p>
<p>Pregnancy, breast-feeding and fertility  </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before this medicine is given. Your doctor or nurse may still recommend that 
you receive Menveo if you are at high risk of infection with meningococcal group A, C, W-135 and Y 
bacteria. </p>
<p>Driving and using machines  </p>
<p>No studies on the effects on the ability to drive and use machines have been performed. 
Dizziness has been very rarely reported following vaccination. This may temporarily affect the ability 
to drive or use machines. </p>
<p>Menveo contains </p>
<p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially 
 sodium-free . 
This medicinal product contains less than 1 mmol potassium (39 mg) per dose, i.e. essentially 
 potassium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take menveo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take menveo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Menveo will be given to you or your child by a doctor or nurse. </p>
<p>The vaccine is usually given into the upper arm muscle (deltoid) for children (from 2 years of age), 
adolescents and adults. Your doctor or nurse will take care to ensure the vaccine is not given into 
a blood vessel and will make sure that it is injected into muscle and not into the skin. </p>
<p>For children (from 2 years of age), adolescents and adults: a single (0.5 mL) injection will be given. </p>
<p>The safety and efficacy of Menveo in children under 2 years of age has not yet been established. There 
are limited data in individuals aged 56-65 and there are no data in subjects aged older than 65 years. </p>
<p>Please tell your doctor if you have received a previous injection with Menveo or another 
meningococcal vaccine. Your doctor will tell you if you need an additional injection of Menveo. </p>
<p>For information on the reconstitution of the vaccine see the section for medical or healthcare 
professionals at the end of this leaflet. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The most common side effects reported during clinical trials usually lasted only one to two days 
and were not usually severe. </p>
<p>In children (from 2 to 10 years of age), the side effects that were reported during clinical trials are 
listed below. </p>
<p>Very common (may affect more than 1 in 10 people): sleepiness, headache, irritability, generally 
feeling unwell, injection site pain, injection site redness (  50 mm), injection site firmness (  50 mm) </p>
<p>Common (may affect up to 1 in 10 people): change in eating habits, nausea, vomiting, diarrhea, rash, 
muscle ache, joint ache, chills, fever  38oC, injection site redness (&gt;50mm) and injection site 
firmness (&gt;50mm) </p>
<p>Uncommon (may affect up to 1 in 100 people): injection site itching </p>
<p>In adolescents (from 11 years of age) and adults, the most common side effects that were reported 
during clinical trials are listed below. </p>
<p>Very common: headache, nausea, injection site pain, injection site redness (  50 mm), injection site 
firmness (  50 mm), muscle ache, generally feeling unwell </p>
<p>Common: rash, injection site redness (&gt; 50 mm), injection site firmness (&gt; 50 mm), joint ache, 
fever   38 C, chills 
Uncommon: dizziness, injection site itching </p>
<p>Side effects that have been reported during marketed use include: 
Rare: enlarged lymph nodes. 
Not known: allergic reactions that may include severe swelling of the lips, mouth, throat (which may 
cause difficulty in swallowing), difficulty breathing with wheezing or coughing, rash and swelling of 
the hands, feet and ankles, loss of consciousness, very low blood pressure; fits (convulsions) including 
fits associated with fever; balance disorder; faint; infection of the skin at the injection site; injection 
site swelling, including extensive swelling of the injected limb. </p>
<p>If a severe allergic reaction occurs tell your doctor straight away or go immediately/ take your child to 
the nearest Accident and Emergency department because urgent medical help may be needed. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store menveo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store menveo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the outer carton after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2 C   8 C). Do not freeze. Keep the vials in the outer carton in order to protect 
from light. </p>
<p>After reconstitution, the product should be used immediately. However, chemical and physical 
stability after reconstitution was demonstrated for 8 hours below 25 C. </p>
<p>Do not throw away any medicines via wastewater or household waste. Your doctor or nurse will 
dispose of this medicine. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Menveo contains </p>
<p>One dose (0.5 mL of the reconstituted vaccine) contains: 
The active substances are: </p>
<p>(Originally contained in the powder) 
* Meningococcal group A oligosaccharide 
10 micrograms 
Conjugated to Corynebacterium diphtheriae CRM197 protein 
16.7 to 33.3 micrograms </p>
<p>(Originally contained in the solution) 
* Meningococcal group C oligosaccharide 
5 micrograms 
Conjugated to Corynebacterium diphtheriae CRM197 protein 
7.1 to 12.5 micrograms </p>
<ul>
<li>
<p>Meningococcal group W-135 oligosaccharide 
5 micrograms 
Conjugated to Corynebacterium diphtheriae CRM197 protein 
3.3 to 8.3 micrograms </p>
</li>
<li>
<p>Meningococcal group Y oligosaccharide 
5 micrograms 
Conjugated to Corynebacterium diphtheriae CRM197 protein 
5.6 to 10.0 micrograms </p>
</li>
</ul>
<p>The other ingredients (excipients) are: </p>
<p>In the powder: potassium dihydrogen phosphate and sucrose. </p>
<p>In the solution: sodium chloride, sodium dihydrogen phosphate monohydrate, sodium hydrogen 
phosphate dihydrate and water for injection (See also end of Section 2). </p>
<p>What Menveo looks like and contents of the pack </p>
<p>Menveo is a powder and a solution for injection. 
Each dose of Menveo is supplied as a:</p>
<ul>
<li>1 Vial containing the MenA Lyophilised Conjugate Component as a white to off-white powder </li>
<li>1 Vial containing the MenCWY Liquid Conjugate Component as clear solution </li>
<li>Pack size of one dose (2 vials), five doses (10 vials) or ten doses (20 vials).<br />
Not all pack sizes may be marketed. </li>
</ul>
<p>The contents of the two components (vial and vial) are to be mixed prior to vaccination 
providing 1 dose of 0.5 mL. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Marketing Authorisation Holder: 
GSK Vaccines S.r.l., 
Via Fiorentina 1, 53100 Siena, 
Italy </p>
<p>Manufacturer: 
GSK Vaccines S.r.l., 
Bellaria-Rosia, 53018 Sovicille (Siena), 
Italy </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
GlaxoSmithKline Pharmaceuticals SA/NV 
T l/Tel: + 32 10 85 52 Lietuva 
GSK Vaccines S.r.l. 
Tel: +370 80000<br />
GSK Vaccines S.r.l. 
 . +359 80018Luxembourg/Luxemburg 
GlaxoSmithKline Pharmaceuticals SA/NV 
T l/Tel: + 32 10 85 52  esk  republika 
GlaxoSmithKline s.r.o. 
Tel: + 420 2 22 00 11 cz.info@gsk.com </p>
<p>Magyarorsz g 
GSK Vaccines S.r.l. 
Tel.: +36 80088Danmark 
GlaxoSmithKline Pharma A/S 
Tlf: + 45 36 35 91 dk-info@gsk.com </p>
<p>Malta 
GSK Vaccines S.r.l. 
Tel: +356 80065Deutschland 
GlaxoSmithKline GmbH &amp; Co. KG 
Tel: +49 (0)89 36044 8de.impfservice@gsk.com<br />
Nederland 
GlaxoSmithKline BV 
Tel: + 31 (0)33 2081Eesti 
GSK Vaccines S.r.l.<br />
Tel: +372 8002Norge 
GlaxoSmithKline AS 
Tlf: + 47 22 70 20 <br />
GlaxoSmithKline   A.E.B.E 
T : + 30 210 68 82  sterreich 
GlaxoSmithKline Pharma GmbH. 
Tel: + 43 (0)1 97075 0 
at.info@gsk.com  </p>
<p>Espa a 
GlaxoSmithKline, S.A. 
Tel: + 34 900 202 es-ci@gsk.com  </p>
<p>Polska 
GSK Services Sp. z o.o. 
Tel.: + 48 (22) 576 9France 
Laboratoire GlaxoSmithKline 
T l: + 33 (0) 1 39 17 84 diam@gsk.com  </p>
<p>Portugal 
GlaxoSmithKline - Produtos Farmac uticos, 
Lda. 
Tel: + 351 21 412 95 FI.PT@gsk.com<br />
Hrvatska 
GSK Vaccines S.r.l. 
Tel.: +385 800787Rom nia 
GSK Vaccines S.r.l. 
Tel: +40 800672Ireland 
GlaxoSmithKline (Ireland) Ltd 
Tel: + 353 (0)1 495 5Slovenija 
GSK Vaccines S.r.l. 
Tel: +386 80688 sland 
Vistor hf.<br />
S mi: +354 535 7Slovensk  republika 
GSK Vaccines S.r.l. 
Tel.: +421 800500Italia 
GlaxoSmithKline S.p.A. 
Tel: +39 (0)45 7741 Suomi/Finland 
GlaxoSmithKline Oy 
Puh/Tel: + 358 10 30 30 <br />
GSK Vaccines S.r.l. 
 : +357 80070Sverige 
GlaxoSmithKline AB 
Tel: + 46 (0)8 638 93 info.produkt@gsk.com<br />
Latvija 
GSK Vaccines S.r.l. 
Tel: +371 80205United Kingdom (Northern Ireland) 
GSK Vaccines S.r.l. 
Tel: +44 (0)800 221 customercontactuk@gsk.com  </p>
<p>This leaflet was last revised in (MM/YYYY)  </p>
<p>Other sources of information  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-c082813e7ff4dad923d73dee6e29eba2
InstanceOf: CompositionUvEpi
Title: "Composition for menveo Package Leaflet"
Description:  "Composition for menveo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc082813e7ff4dad923d73dee6e29eba2)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - menveo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du eller dit barn får Menveo </li>
<li>Sådan bruges Menveo </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What menveo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What menveo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Menveo er en vaccine, der benyttes til aktiv beskyttelse af børn (fra 2 år), unge og voksne med 
risiko for at blive udsat for en bakterie, der kaldes Neisseria meningitidis, serogruppe A, C, W-135 og 
Y, som forebyggelse mod sygdom. Vaccinen virker ved at stimulere kroppens egen beskyttelse 
(dannelse af antistoffer) mod disse bakterier. </p>
<p>Neisseria meningitidis-gruppe A, C, W-135 og Y-bakterier kan medføre alvorlige og til tider 
livstruende infektioner som meningitis (hjernehindebetændelse) og sepsis (blodforgiftning). </p>
<p>Menveo kan ikke medføre bakteriel meningitis. Denne vaccine indeholder et protein (kaldet CRM197) 
fra den bakterie, der forårsager difteri. Menveo beskytter ikke mod difteri. Dette betyder, at du 
(eller dit barn) skal have andre vaccinationer mod difteri, når tiden er inde til dette, eller når lægen 
anbefaler det. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take menveo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take menveo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du eller dit barn må ikke få Menveo, hvis du/dit barn  </p>
<ul>
<li>nogensinde har haft en allergisk reaktion over for det aktive stof eller et af de øvrige 
indholdsstoffer i vaccinen (angivet i punkt 6) </li>
<li>nogensinde har haft en allergisk reaktion over for difteritoksoid (et stof, der anvendes i en række 
andre vacciner) </li>
<li>har en sygdom med høj feber. Dog er let feber eller infektion i de øvre luftveje 
(for eksempel forkølelse) ikke i sig selv grund til at udskyde vaccination. </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen eller sygeplejersken, før du eller dit barn bruger Menveo:</p>
<ul>
<li>hvis du eller dit barn har et svækket immunsystem. Der er begrænset kendskab til effektiviteten<br />
af Menveo hos personer, hvor immunsystemet fungerer dårligere på grund af immunhæmmende 
medicin, hiv-infektion eller andre årsager. Effektiviteten af Menveo er muligvis nedsat hos disse 
personer. </li>
<li>hvis du eller dit barn har hæmofili eller en anden lidelse, der kan forhindre blodet i at størkne, </li>
</ul>
<p>f.eks. hvis du tager blodfortyndende medicin (antikoagulanter). 
- hvis du eller dit barn modtager behandling, som blokerer den del af immunsystemet, kendt som 
komplement aktivering, såsom eculizumab. Selvom du er blevet vaccineret med Menveo, er du 
stadig i øget risiko for sygdom forårsagt af Neisseria meningitidis grupperne A, C, W-135 og Y 
bakterier. </p>
<p>Besvimelse og følelse af svaghed eller andre stressrelaterede reaktioner kan opstå i forbindelse med 
enhver injektion med kanyle. Fortæl det til lægen eller sundhedspersonalet, hvis du tidligere har haft 
en sådan reaktion. </p>
<p>Denne vaccine beskytter kun mod meningokokgruppe A, C, W-135, og Y bakterier. Den yder ingen 
beskyttelse mod andre typer af meningokokbakterier, som ikke findes i vaccinen, eller andre årsager 
til meningitis og sepsis (blodforgiftning). </p>
<p>Som det gælder for alle vacciner, er det ikke sikkert, at Menveo giver fuld beskyttelse til alle, 
som får vaccinen. </p>
<p>Hvis du eller dit barn har fået en dosis Menveo for mere end et år siden og stadig er i særlig risiko 
for at blive udsat for meningokokgruppe A-bakterien, kan det overvejes at give en boosterdosis for 
at vedligeholde beskyttelsen. Din læge vil fortælle dig det, hvis du skal have en boosterdosis. </p>
<p>Brug af anden medicin sammen med Menveo </p>
<p>Fortæl altid lægen eller sygeplejersken, hvis du tager anden medicin, for nylig har taget anden medicin 
eller planlægger at tage anden medicin. </p>
<p>Menveo kan gives sammen med andre vacciner, men indsprøjtning af eventuelle andre vacciner skal 
fortrinsvist gives i den modsatte arm i forhold til den, den bliver brugt til Menveo. </p>
<p>Andre vacciner omfatter følgende: vaccine mod stivkrampe, difteri og kighoste (Tdap), vaccine mod 
humant papillomavirus (HPV), gul feber, tyfus (Vi polysaccharid), japansk encefalitis, rabies, hepatitis 
A og B, og meningokokgruppe B (Bexsero). </p>
<p>Virkningen af Menveo kan blive nedsat, hvis du vaccineres, mens du tager medicin, der undertrykker 
immunsystemet. </p>
<p>Der skal anvendes forskellige indsprøjtningssteder, hvis der gives mere end én vaccine på samme tid. </p>
<p>Graviditet, amning og frugtbarhed  </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, 
skal du spørge din læge til råds, før du får dette lægemiddel. Din læge eller sygeplejerske kan stadig 
anbefale, at du får Menveo, hvis du har stor risiko for infektion med meningokokgruppe A-, C-, W-
135- og Y-bakterier. </p>
<p>Trafik- og arbejdssikkerhed  </p>
<p>Påvirkningen af evnen til at køre og betjene maskiner er ikke undersøgt. 
Svimmelhed efter vaccination er rapporteret i sjældne tilfælde. Dette kan midlertidigt påvirke evnen til 
at køre eller benytte maskiner. </p>
<p>Menveo indeholder </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, dvs. det er i det 
væsentlige natriumfrit. 
Dette lægemiddel indeholder mindre end 1 mmol (39 mg) kalium pr. dosis, dvs. det er i det væsentlige 
kaliumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take menveo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take menveo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Menveo vil blive givet til dig eller dit barn af en læge eller sygeplejerske. </p>
<p>Vaccinen gives normalt i overarmsmusklen (deltoideus) hos børn (fra 2 år), unge og voksne. Lægen 
eller sygeplejersken vil sørge for, at vaccinen ikke gives i et blodkar og vil sikre, at den injiceres 
i en muskel og ikke i huden. </p>
<p>Til børn (fra 2 år), unge og voksne: der gives en enkelt (0,5 ml) indsprøjtning. </p>
<p>Menveos sikkerhed og virkning hos børn under 2 år er endnu ikke klarlagt. Der er begrænset erfaring 
med vaccinen hos personer i alderen 56-65 år, og der er ingen data for personer over 65 år. </p>
<p>Fortæl det til lægen, hvis du tidligere har fået en injektion med Menveo eller en anden 
meningokokvaccine. Din læge vil fortælle dig, om du har behov for endnu en injektion af Menveo. </p>
<p>For information om blanding (rekonstitution) af vaccinen, se afsnittet for læger og sundhedspersonale 
sidst i denne indlægsseddel. </p>
<p>Spørg lægen eller sygeplejersken, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>De almindeligste bivirkninger, som er indberettet i kliniske studier, varede normalt kun en eller 
to dage og var ikke alvorlige. </p>
<p>De bivirkninger, der blev indberettet i kliniske studier hos børn (fra 2 til 10 år), er anført nedenfor. </p>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer): søvnighed, hovedpine, 
irritabilitet, generel utilpashed, smerte på injektionsstedet, rødme på injektionsstedet (≤ 50 mm), 
hårdhed på injektionsstedet (≤ 50 mm) </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer): ændringer i spisevaner, kvalme, 
opkastning, diaré, udslæt, muskelsmerter, ledsmerter, kulderystelser, feber ≥ 38 °C, rødme på 
injektionsstedet (&gt; 50 mm) og hårdhed på injektionsstedet (&gt; 50 mm) </p>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer): kløe på injektionsstedet </p>
<p>De almindeligste bivirkninger, der blev indberettet i kliniske forsøg hos unge (fra 11 år) og voksne, 
er anført nedenfor. </p>
<p>Meget almindelige: hovedpine, kvalme, smerte på injektionsstedet, rødme på injektionsstedet 
(≤ 50 mm), hårdhed på injektionsstedet (≤ 50 mm), muskelsmerter, generel utilpashed </p>
<p>Almindelige: udslæt, rødme på injektionsstedet (&gt; 50 mm), hårdhed på injektionsstedet (&gt; 50 mm), 
ledsmerter, feber ≥ 38 °C, kulderystelser </p>
<p>Ikke almindelige: svimmelhed, kløe på injektionsstedet </p>
<p>Følgende bivirkninger er blevet rapporteret under brug efter markedsføringen: </p>
<p>Sjælden: hævede lymfekirtler 
Ikke kendt: allergiske reaktioner, som kan omfatte svær hævelse af læber, mund, hals (kan medføre 
synkebesvær), åndedrætsbesvær med hvæsen eller hoste, udslæt og hævede hænder, fødder og ankler, 
bevidstløshed, meget lavt blodtryk; krampeanfald, herunder feberkramper; balanceforstyrrelser; 
besvimelse; infektion i huden på injektionsstedet; hævelse på injektionsstedet, herunder kraftig 
hævelse af den injicerede arm/ben. </p>
<p>Hvis der opstår en kraftig allergisk reaktion, skal du straks søge læge eller tage til/bringe dit barn til 
den nærmeste skadestue, da hurtig lægehjælp kan være påkrævet. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store menveo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store menveo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken efter EXP. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 °C - 8 °C). Må ikke nedfryses. Opbevar hætteglassene i den ydre emballage 
for at beskytte mod lys. </p>
<p>Efter blanding skal præparatet anvendes straks. Der er dog påvist kemisk og fysisk stabilitet efter 
blanding i op til 8 timer ved temperaturer under 25 °C. </p>
<p>Af hensyn til miljøet må du ikke smide medicinrester i afløbet eller skraldespanden. Din læge eller 
sundhedspersonalet vil bortskaffe denne medicin. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Menveo indeholder: </p>
<p>En dosis (0,5 ml rekonstitueret vaccine) indeholder: 
Aktive stoffer: </p>
<p>(Oprindeligt indhold i pulver) </p>
<ul>
<li>Meningokokgruppe A-oligosaccharid 
10 mikrogram 
Konjugeret til Corynebacterium diphtheriae CRM197-protein 
16,7 til 33,3 mikrogram </li>
</ul>
<p>(Oprindeligt indhold i opløsningen) </p>
<ul>
<li>
<p>Meningokokgruppe C-oligosaccharid 
5 mikrogram 
Konjugeret til Corynebacterium diphtheriae CRM197-protein 
7,1 til 12,5 mikrogram </p>
</li>
<li>
<p>Meningokokgruppe W-135-oligosaccharid 
5 mikrogram 
Konjugeret til Corynebacterium diphtheriae CRM197-protein 
3,3 til 8,3 mikrogram </p>
</li>
<li>
<p>Meningokokgruppe Y-oligosaccharid 
5 mikrogram 
Konjugeret til Corynebacterium diphtheriae CRM197-protein 
5,6 til 10,0 mikrogram </p>
</li>
</ul>
<p>Øvrige indholdsstoffer (hjælpestoffer): </p>
<p>I pulveret: kaliumdihydrogenphosphat og saccharose. </p>
<p>I opløsningen: natriumchlorid, natriumdihydrogenphosphatmonohydrat, dinatriumphosphatdihydrat og 
vand til injektionsvæsker (se også sidst i punkt 2). </p>
<p>Udseende og pakningsstørrelser </p>
<p>Menveo er et pulver og en opløsning til injektion. 
Hver dosis af Menveo leveres som:</p>
<ul>
<li>1 hætteglas indeholdende MenA frysetørret konjugat komponent som et hvidt til 
off-white pulver </li>
<li>1 hætteglas indeholdende MenCWY flydende konjugeret komponent som en klar opløsning </li>
<li>Pakningsstørrelser på én dosis (2 hætteglas), 5 doser (10 hætteglas) eller 10 doser (20  </li>
</ul>
<p>hætteglas).  </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indholdet af de to komponenter (hætteglas og hætteglas) blandes inden vaccination 
og giver 1 dosis på 0,5 ml. </p>
<p>Indehaveren af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen: 
GSK Vaccines S.r.l., 
Via Fiorentina 1, 53100 Siena, 
Italien </p>
<p>Fremstiller: 
GSK Vaccines S.r.l., 
Bellaria-Rosia, 53018, Sovicille (Siena), 
Italien </p>
<p>Hvis du vil have yderligere oplysninger om Menveo, skal du henvende dig til den lokale repræsentant: </p>
<p>België/Belgique/Belgien 
GlaxoSmithKline Pharmaceuticals SA./NV 
Tél/Tel: + 32 10 85 52 00<br />
Lietuva 
GSK Vaccines S.r.l. 
Tel: +370 80000<br />
България 
GSK Vaccines S.r.l. 
Тел. +359 80018Luxembourg/Luxemburg 
GlaxoSmithKline Pharmaceuticals SA./NV 
Tél/Tel: + 32 10 85 52<br />
Česká republika 
GlaxoSmithKline s.r.o. 
Tel: + 420 2 22 00 11 cz.info@gsk.com </p>
<p>Magyarország 
GSK Vaccines S.r.l. 
Tel.: +36 80088Danmark 
GlaxoSmithKline Pharma A/S 
Tlf: + 45 36 35 91 dk-info@gsk.com 
Malta 
GSK Vaccines S.r.l. 
Tel: +356 80065004  </p>
<p>Deutschland 
GlaxoSmithKline GmbH &amp; Co. KG 
Tel: +49 (0)89 36044 8de.impfservice@gsk.com  </p>
<p>Nederland 
GlaxoSmithKline BV 
Tel: (0)33 2081 
Eesti 
GSK Vaccines S.r.l.<br />
Tel: +372 8002<br />
Norge 
GlaxoSmithKline AS 
Tlf: + 47 22 70 20<br />
Ελλάδα 
GlaxoSmithKline Μονοπρόσωπη A.E.B.E 
Tηλ: + 30 210 68 82 100<br />
Österreich 
GlaxoSmithKline Pharma GmbH. 
Tel: + 43 (0) 1 97075 0 
at.info@gsk.com  </p>
<p>España 
GlaxoSmithKline, S.A. 
Tel: + 34 900 202 es-ci@gsk.com  </p>
<p>Polska 
GSK Services Sp. z o.o. 
Tel.: + 48 (22) 576 9000<br />
France 
Laboratoire GlaxoSmithKline 
Tél: + 33 (0) 1 39 17 84 diam@gsk.com  </p>
<p>Portugal 
GlaxoSmithKline - Produtos Farmacêuticos, 
Lda. 
Tel: + 351 21 412 95 FI.PT@gsk.com  </p>
<p>Hrvatska 
GSK Vaccines S.r.l. 
Tel.: +385 800787089  </p>
<p>România 
GSK Vaccines S.r.l. 
Tel: +40 800672Ireland 
GlaxoSmithKline (Ireland) Ltd 
Tel: + 353 (0)1 495 5000  </p>
<p>Slovenija 
GSK Vaccines S.r.l. 
Tel: +386 80688<br />
Ísland 
Vistor hf.<br />
Sími: +354 535 7000  </p>
<p>Slovenská republika 
GSK Vaccines S.r.l. 
Tel: +421 800500<br />
Italia 
GlaxoSmithKline S.p.A. 
Tel: +39 (0)45 7741<br />
Suomi/Finland 
GlaxoSmithKline Oy 
Puh/Tel: + 358 10 30 30<br />
Κύπρος 
GSK Vaccines S.r.l. 
Τηλ: +357 80070  </p>
<p>Sverige 
GlaxoSmithKline AB 
Tel: + 46 (0)8 638 93 info.produkt@gsk.com<br />
Latvija 
GSK Vaccines S.r.l. 
Tel: +371 80205<br />
United Kingdom (Northern Ireland) 
GSK Vaccines S.r.l. 
Tel: + 44 (0)800 221 customercontactuk@gsk.com  </p>
<p>Denne indlægsseddel blev senest ændret den {MM/ÅÅÅÅ} </p>
<p>Andre informationskilder  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside. </p>
<hr />
<p>Følgende oplysninger er tiltænkt læger og sundhedspersonale: </p>
<p>Rekonstitution af vaccinen </p>
<p>Før administration skal pulveret rekonstitueres med opløsningen. </p>
<p>Indholdet i de to hætteglas (MenA-pulver og MenCWY-opløsning) skal blandes før vaccination, så der 
opnås 1 dosis på 0,5 ml. </p>
<p>Med en sprøjte og en egnet kanyle (21G, 40 mm lang eller 21G, 1 ½" lang) trækkes hele indholdet 
ud af hætteglasset med opløsningen og injiceres i hætteglasset med pulver for at rekonstituere MenA 
konjugeret komponent. </p>
<p>Vend hætteglasset på hovedet, ryst det kraftigt, og træk derefter 0,5 ml rekonstitueret produkt op. 
Bemærk, at det er normalt, at der er en lille mængde væske tilbage i hætteglasset efter optrækning 
af dosis. Før injektion skiftes til en kanyle, der er egnet til administration. Tjek, at der ikke er 
luftbobler i sprøjten, inden vaccinen injiceres. </p>
<p>Efter rekonstitution er vaccinen en klar, farveløs til lysegul opløsning uden synlige fremmedpartikler. 
I tilfælde af fremmedpartikler og/eller synlige forandringer kasseres vaccinen. </p>
<p>Menveo gives som en intramuskulær injektion, helst i musculus deltoideus. </p>
<p>Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-c082813e7ff4dad923d73dee6e29eba2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for menveo Package Leaflet for language en"
Description: "ePI document Bundle for menveo Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-c082813e7ff4dad923d73dee6e29eba2"
* entry[0].resource = composition-en-c082813e7ff4dad923d73dee6e29eba2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpc082813e7ff4dad923d73dee6e29eba2"
* entry[=].resource = mpc082813e7ff4dad923d73dee6e29eba2
                            
                    
Instance: bundlepackageleaflet-da-c082813e7ff4dad923d73dee6e29eba2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for menveo Package Leaflet for language da"
Description: "ePI document Bundle for menveo Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-c082813e7ff4dad923d73dee6e29eba2"
* entry[0].resource = composition-da-c082813e7ff4dad923d73dee6e29eba2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpc082813e7ff4dad923d73dee6e29eba2"
* entry[=].resource = mpc082813e7ff4dad923d73dee6e29eba2
                            
                    



Instance: mpc082813e7ff4dad923d73dee6e29eba2
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Menveo powder and solution for solution for injection"
Description: "Menveo powder and solution for solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/10/614/002"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Menveo powder and solution for solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: c082813e7ff4dad923d73dee6e29eba2ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "menveo"

* status = #current
* mode = #working

* title = "List of all ePIs associated with menveo"

* subject = Reference(mpc082813e7ff4dad923d73dee6e29eba2)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#menveo "menveo"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-c082813e7ff4dad923d73dee6e29eba2) // menveo en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-c082813e7ff4dad923d73dee6e29eba2) // menveo da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-c082813e7ff4dad923d73dee6e29eba2
InstanceOf: List

* insert c082813e7ff4dad923d73dee6e29eba2ListRuleset
    